Affiliation:
1. Sidi Mohamed Ben Abdellah University
Abstract
Abstract
TRPV1 is a promising therapeutic target given its involvement in pain management and inflammation. TRPV1 antagonists are increasingly sought after for their analgesic, anti-inflammatory and antitumor properties with fewer side effects. This study focused on the design of new effective TRPV1 antagonists by replacing the pyridine ring of BCTC with a pyrimidine ring. Significant 3D-QSAR models were developed using CoMSIA and CoMFA methods and showed a satisfactory correlation between experimental and predicted activity (Q2 = 0.715; R2 = 0.988; SEE = 0.048). Electrostatic, hydrophobic fields and hydrogen bond acceptors contributed significantly to the biological activity of studied compounds. Molecular docking analysis validated the 3D-QSAR models and explained the interactions of the most active ligands with the binding site. These results permitted prediction of new compounds, whose pharmacokinetic properties, toxicity and pharmacodynamics effects were assessed using ADMET and drug similarity.
Publisher
Research Square Platform LLC
Reference36 articles.
1. Chronic pain acceptance: Relations to opioid misuse and pain management motives among individuals with chronic low back pain;Smit T;Addict. Behav.,2023
2. Clinical Phenotyping for Pain Mechanisms in Urologic Chronic Pelvic Pain Syndromes: A MAPP Research Network Study;Schrepf A;J. Pain,2022
3. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature;Reilly RM;J. Pharmacol. Exp. Ther.,2012
4. Aghazadeh Tabrizi, M., Baraldi, P.G., Baraldi, S., Gessi, S., Merighi, S., Borea, P.A.: Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists, (2017)
5. Prediction of Novel TRPV1 Antagonist: A Combination of 3D-QSAR, Molecular Docking, MD Simulations and ADMET Prediction;Toughzaoui A;Phys. Chem. Res.,2022